Innovent Biologics: Total revenue of 13.04 billion yuan in 2025, up 38.4% year-on-year

NightAirdropper · 2026-03-27T19:09:56+00:00

Gelonghui March 26 | Cinda Biologics(1801.HK) announced on the Hong Kong Stock Exchange that the total revenue for the year reached RMB 13.0415 billion, a year-on-year increase of 38.4%. Under International Financial Reporting Standards (IFRS), net profit reached RMB 813.6 million, compared to a loss of RMB 94.63 million last year, turning profitable year-on-year. Non-IFRS net profit increased to RMB 1.7231 billion, a year-on-year growth of 419.6%.

NightAirdropper

2026-03-27 19:09:56

Gelonghui March 26 | Sinovac Biotech (1801.HK) announced on the Hong Kong Stock Exchange that it achieved total revenue of RMB 13.0415 billion for the year, a year-on-year increase of 38.4%. The net profit under International Financial Reporting Standards (IFRS) reached RMB 813.6 million, reversing a loss of RMB 94.63 million last year. Non-IFRS net profit grew to RMB 1.7231 billion, a year-on-year increase of 419.6%.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes